A brainwave biomarker licensed by digital therapeutic startup Empower Therapeutics Inc. showed potential to identify patients with high sensitivity to pain. In a new study carried out by researchers at the University of Birmingham, U.K., the biomarker predicted which patients had a pain score of seven out of 10 or higher (severe pain) following lung surgery.
Bostongene LLC topped up its coffers with $150 million series B round, pushing its valuation over $1 billion and into unicorn territory. The med-tech industry’s latest mystical equine can whinny all the way to the bank with two other newcomers to the elite corral: Mindmaze SA and Freenome Inc., which jumped the $1 billion valuation hurdle in March and February, respectively.
Cefaly Technology sprl reported results from a phase III clinical trial showing that two-hour treatment with its Cefaly Dual external trigeminal nerve stimulation (e-TNS) device is a safe and effective nonpharmaceutical option for acute migraine treatment in a nonhospital setting.
Biocircuit Technologies Inc. has joined forces with Smithfield Bioscience Inc. to scale up a medical alternative to sutures for repairing nerves on the peripheral side of the body damaged in an accident or during surgery. Nerve Tape is an implantable device composed of decellularized porcine tissue embedded with microhooks that attach to damaged nerves and may heal them more quickly and safely than conventional sutures.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Moleculight, Paige.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: AHI, Battelle, Healthy.io, Merck, Milliporesigma, Pixcell, Promega, Soulbrain, Spark Biomedical, Stilla, United Makgroup, Vertica.
Elekta AB signed a commercial agreement with GE Healthcare Co. Ltd. to expand hospital access to radiotherapy. Marlborough, Mass.-based GE Healthcare said it will combine its precision imaging solutions with Elekta’s radiation therapy portfolio to provide hospitals worldwide with a more comprehensive oncology offering.
As was the case with left atrial appendage closure, renal denervation (RD) as a treatment for hypertension has proven to be difficult to move along into routine clinical usage. New data for a study sponsored by Medtronic plc showed that RD offers a statistically significant improvement over sham treatment in reducing hypertension, but the data do not seem to suggest that patients will be able to drop their antihypertensive medications after RD treatment.
RSS
